Top Markets
Coin of the day
ENvue Medical, Inc. ENvue Medical, Inc.

ENvue Medical, Inc.

FEED
Rank in Stocks #35224
NanoVibronix, Inc. focuses on developing non-surgical medical devices that... NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.
Share Price
$0.4574
Last synced: 2026-08-14
Market Cap
$4.25M
Change (1 day)
20.05%
Change (1 year)
-
Country
US
Trade ENvue Medical, Inc. (FEED)

Category

P/E ratio for ENvue Medical, Inc. (FEED)
P/E ratio as of 2026 TTM: 0
According to ENvue Medical, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for ENvue Medical, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.